Patents by Inventor Charlott Brunmark

Charlott Brunmark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
    Patent number: 11883405
    Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: January 30, 2024
    Assignee: AMPLIO PHARMA AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
  • Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
    Patent number: 10703723
    Abstract: The present invention relates to new compounds of formula I and pharmaceutically acceptable salts and/or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and/or TNF-alpha and or nuclear factor kappa B (NFKB) and/or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: July 7, 2020
    Assignee: TRULY TRANSLATIONAL SWEDEN AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
  • A PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF METHOTREXATE AND NOVOBIOCIN, AND THE USE OF SAID COMPOSITION IN THERAPY
    Publication number: 20200101074
    Abstract: The present invention relates to a pharmaceutical product comprising a combination of methotrexate and novobiocin, or any pharmaceutically acceptable salts of said compounds, and a pharmaceutical composition comprising (i) a therapeutic amount of methotrexate or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent, (ii) a non-therapeutic amount of novobiocin or any pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipient, carrier or diluent. The invention further relates to a use of the pharmaceutical product and composition in therapy, such as prevention, progression prophylaxis and/or treatment of autoimmune diseases.
    Type: Application
    Filed: May 31, 2018
    Publication date: April 2, 2020
    Applicant: Truly Translational Sweden AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt
  • PRODRUGS OF SULFASALAZINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20200017446
    Abstract: The present invention relates to new compounds of formula I and pharmaceutically acceptable salts and/or co-crystals thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as medicaments for the prevention, prophylaxis of progression, and/or treatment of a disease in which modulation of extracellular (chemotactic) cytokines and/or TNF-alpha and or nuclear factor kappa B (NFKB) and/or inflammatory cells is beneficial, such as autoimmune diseases, like rheumatoid arthritis, oligoarthritis, spondyloarthropathy, psoriatic arthritis, psoriasis and inflammatory bowel diseases, such as Crohns' disease and ulcerative colitis.
    Type: Application
    Filed: March 8, 2018
    Publication date: January 16, 2020
    Applicant: Truly Translational Sweden AB
    Inventors: Marguérite Mascha Mensonides-Harsema, Charlott Brunmark, Karin von Wachenfeldt